Press Releases Investors News 2021202020192018201720162015Pre 2015 13th January 2021 First Patient Dosing in Phase III SG018 Trial 18th December 2020 COVID-19 Clinical Programme Update 13th November 2020 Lancet Respiratory Medicine publishes Phase 2 data 2nd November 2020 Result of General Meeting and Total Voting Rights 2nd November 2020 Result of Open Offer 15th October 2020 Results of Placing 14th October 2020 Placing and Open Offer 2nd October 2020 Appointment of Joint Broker 29th September 2020 Interim results for the six months ended 30 June 2020 29th September 2020 Synairgen and Clinigen sign Managed Access Program agreement with SNG001 for treatment of hospitalised patients with COVID-19 9th September 2020 Synairgen IP Update 8th September 2020 Positive interim analysis of SNG001 in COPD 21st July 2020 Clarification Regarding COVID-19 Trial 20th July 2020 Positive results from trial of SNG001 in hospitalised COVID-19 patients 29th June 2020 Result of AGM 18th June 2020 National expansion of home-based COVID-19 trial 3rd June 2020 Posting of Annual Report and Notice of AGM 28th May 2020 Recruitment of Hospitalised Patients in COVID-19 Trial Completed 26th May 2020 Initiation of SNG001 in home setting 26th May 2020 Preliminary statement of results for the year ended 31 December 2019 30th April 2020 Approval received to extend SG016 study of SNG001 in COVID-19 to initiate patients in the home environment 14th April 2020 Result of General Meeting 31st March 2020 Commencement of dosing in COVID-19 trial 26th March 2020 Result of fundraising 25th March 2020 Proposed fundraising 18th March 2020 Synairgen to start trial of SNG001 in COVID-19 imminently 30 September 2019 Interim results for the six months ended 30 June 2019 27 September 2019 Phase II Biomarker Data for SNG001 to be presented at European Respiratory Society 24th July 2019 Phase II Clinical Trial Update in Patients with COPD 3rd June 2019 Result of AGM 18th April 2019 Directorate Change, Posting of Annual Report, and Notice of AGM 14th March 2019 Positive DSMC Review of Phase II Study for SNG001 25th February 2019 Preliminary statement of results for the year ended 31 December 2018 17th January 2019 Update on LOXL2 programme with Pharmaxis 22nd October 2018 Synairgen commences dosing in part 2 of its Phase II clinical trial in patients with COPD 12th October 2018 Result of General Meeting 25th September 2018 Result of Fundraise 25th September 2018 Proposed Fundraise to raise c.£2.9 million 25th September 2018 Interim results for the six months ended 30 June 2018 28th June 2018 Positive SNG001 Biomarker Data in COPD Patients 22nd June 2018 Result of Synairgen AGM 22nd June 2018 Synairgen Safety Data with SNG001 in COPD Patients 17th May 2018 Posting of Annual Report and Notice of AGM 15th March 2018 Preliminary statement of results for the year ended 31 December 2017 7th February 2018 Synairgen starts dosing in phase II COPD study 27th December 2017 Data update from clinical trial of inhaled interferon beta (SNG001) and clinical plan for COPD 14th December 2017 Update on LOXL2 Programme and Collaboration with Pharmaxis 27th September 2017 Interim results for the six months ended 30 June 2017 6th September 2017 LOXL2 Inhibitor Update 28th June 2017 Result of 2017 Annual General Meeting 5th June 2017 Posting of Annual Report and Notice of AGM 17th May 2017 Preliminary statement of results for the year ended 31 December 2016 27th April 2017 AZD9412 Update 10th March 2017 Additional Positive Data in Lung Fibrosis 12th October 2016 AZD9412 Clinical Trial Update 22nd September 2016 Interim results for the six months ended 30 June 2016 8th September 2016 Notice of Interim Results 14th June 2016 Results of 2016 Annual General Meeting 17th May 2016 Posting of Annual Report and Notice of AGM 22nd March 2016 Preliminary statement of results for the year ended 31 December 2015 22nd March 2016 Positive LOXL2 results 3rd March 2016 Notice of Preliminary Results 16th September 2015 Interim results for the six months ended 30 June 2015 21st August 2015 Notice of Interim Results 5th August 2015 Research collaboration with Pharmaxis in IPF 2nd July 2015 AstraZeneca commences AZD9412 Phase II trial in severe asthma 22nd June 2015 Results of 2015 Annual General Meeting 15th May 2015 Notice of Annual General Meeting 22nd April 2015 Posting of Annual Report and Accounts 3rd March 2015 Preliminary statement of results for the year ended 31 December 2014 25th September 2014 Interim results for the six months ended 30 June 2014 17th September 2014 Notice of Interim Results 4th July 2014 Placing 12th June 2014 AstraZeneca Licence Deal 9th June 2014 Result of General Meeting 16th May 2014 Notice of Annual General Meeting 9th May 2014 Notice of Report and Accounts 20th March 2014 Preliminary statement of results for the year ended 31 December 2013 5th March 2014 Licensing update, placing to raise £1.5m and notice of results 12th August 2013 Interim results for the six months ended 30 June 2013 18th July 2013 Positive Anti-Inflammatory and Anti-Viral Data 10th June 2013 Result of Annual General Meeting 9th May 2013 Notice of Annual General Meeting 9th April 2013 Notice of Report and Accounts 13th February 2013 Preliminary statement of results for the year ended 31 December 2012 5th December 2012 Trading Update 30th October 2012 Director’s dealing 10th August 2012 Interim results for the six months ended 30 June 2012 18th July 2012 Placing 25th June 2012 Result of General Meeting 1 2 3 … 6 »